United States · Bill · S
S. 660 (116th)
Efficiency and Transparency in Petitions Act
Introduced
5 March 2019
Last action
—
Status
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sponsors
—
Subjects
Discovery layer
Source updated
21 April 2025
Summary
Efficiency and Transparency in Petitions Act This bill requires a petition regarding a pending generic drug or biological product application to be submitted to the Food and Drug Administration (FDA) within one year of when the petitioner discovers the issue that is the basis for the petition. The FDA may grant a waiver of the one-year deadline.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
3 official files
Introduced in Senate (text)
Introduced in Senate · EN · 5 March 2019
Introduced in Senate (PDF)
Introduced in Senate · EN · 5 March 2019
Introduced in Senate
summary · EN · 5 March 2019
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/116th-congress/senate-bill/660
- Open data entity: https://api.congress.gov/v3/bill/116/s/660